EU News
Printable version

European Health Union: Commission establishes portfolio of 10 most promising treatments for COVID-19

Delivering on a key action from the EU Strategy on COVID-19 Therapeutics, the Commission is establishing a portfolio of 10 potential COVID-19 therapeutics. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency.

Vaccination against COVID-19 offers the best preventive protection against infection, severe disease, loss of life and long-term consequences of illness. While vaccination offers the best way to end the pandemic and get back to normal life, in parallel, we are ensuring that the COVID-19 therapeutics are available to treat those who are infected.

Vice-President for Promoting our European Way of Life, Margaritis Schinas recently said:

As we continue to face the challenge of COVID-19, it is important to shield ourselves in addition to vaccination. The establishment of 10 COVID-19 therapeutics will ensure that citizens receive the most promising treatments against the virus.”

Commissioner for Health and Food Safety, Stella Kyriakides, recently said:

Vaccination is the only tool to prevent COVID hospitalisations and deaths, and as such, it is the only way out of this pandemic. In the meantime however, COVID-19 patients do need safe and effective treatments to fight the infection, improve their prospect of a swift recovery, reduce hospitalisations and most importantly, to prevent loss of life. We have already signed four joint procurement contracts for different COVID-19 treatments and we stand ready to negotiate moreOur goal is to authorise at least three therapeutics in the coming weeks and possibly two more by the end of the year and help Member States gain access to them as soon as possible.”

The EU Strategy on COVID-19 Therapeutics is an integral element of the work to build a strong European Health Union, and is modelled on the successful EU Vaccines Strategy.

A group of independent scientific experts has screened 82 therapeutic candidates in late stage clinical development and identified 10 candidates as the most promising for the EU portfolio of COVID-19 treatments, taking into account that different types of products are needed for different patient populations and at different stages and severity of the disease. The list of ten is divided in three categories of treatments and will continue to evolve as new scientific evidence emerges:

  • Antiviral monoclonal antibodies that are most efficacious in the earliest stages of infection:       
    • Ronapreve, a combination of two monocolonal antibodies casirivimab and imdevimab from Regeneron Pharmaceuticals and Roche.
    • Xevudy (sotrovimab) from Vir Biotechnology and GlaxoSmithKline.
    • Evusheld, a combination of two monoclonal antibodies tixagevimab and cilgavimab from AstraZeneca.
  • Oral antivirals for use as quickly as possible after the infection:
    • Molnupiravir from Ridgeback Biotherapeutics and MSD.
    • PF-07321332 from Pfizer.
    • AT-527 from Atea Pharmaceuticals and Roche.
  • Immunomodulators to treat hospitalised patients:  
    • Actemra (tocilizumab) from Roche Holding.
    • Kineret (anakinra) from Swedish Orphan Biovitrum.
    • Olumiant (baricitinib) from Eli Lilly.
    • Lenzimulab from Humaningen.

Click here for the full press release

 

Original article link: https://ec.europa.eu/commission/presscorner/detail/en/IP_21_5366

Share this article

Latest News from
EU News

OnDemand Webinar Event: How Southampton City Council reduced enquiries by 30,000 with AI